Glucocorticoid receptor modulators
AssigneePfizer Inc.
InventorsRobert L. Dow, Kevin K. Liu, Bradley P. Morgan, Andrew G. Swick
Life of this patent
Estimating the term…
Abstract
The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonist and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides intermediates and processes for preparing these compounds. 1
Claims104
A compound of formula I
- 62
- an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug;
- wherein m is 1 or 2;
- ——— represents an optional bond;
- A is selected from the group consisting of
- 63
- G, H and I together with 2 carbon atoms from the A-ring or 2 carbon atoms from the B-ring form a 5-membered heterocyclic ring comprising one or more N, O or S atoms;
- provided that there is at most one of O and S per ring;
- J, K, L and M together with 2 carbon atoms from the B-ring forms a 6-membered heterocyclic ring comprising 1 or more N atoms;
- X is a) absent, b) —CH2—, c) —CH(OH)— or d) —C(O)—;
- R1 is a) —H, b) —Z—CF3, c) —(C1-C6)alkyl, d) —(C2-C6)alkenyl, e) —(C2-C6)alkynyl, f) —CHO, g) —CH═N—OR12, h) —Z—C(O)OR12, i) —Z—C(O)—NR12R13, j) —Z—C(O)—NR12—Z-het, k) —Z—NR12R13, l) —Z—NR12het, m) —Z-het, n) —Z—O-het, o) —Z-aryl′, p) —Z—O-aryl′, q) —CHOH-aryl′ or r) —C(O)-aryl′ wherein aryl′ in substituents o) to r) is substituted independently with 0, 1 or 2 of the following:
- —Z—OH, —Z—NR12R13, —Z—NR12-het, —C(O)NR12R13, —C(O)O(C1-C6)alkyl, —C(O)OH, —C(O)-het, —NR12—(C(O)—C1-C6)alkyl, —NR12—C(O)—(C2-C6)alkenyl, —NR12—C(O)—(C2-C6)alkynyl, —NR12—C(O)—Z-het, —CN, —Z-het, —O—(C1-C3)alkyl-C(O)—NR12R13, —O—(C1-C3)alkyl-C(O)O(C1-C6)alkyl, —NR12—Z—C(O)O(C1-C6)alkyl, —N(Z—C(O)O(C1-C6)alkyl)2, —NR12—Z—C(O)—NR12R13, —Z—NR12—SO2—R13, —NR12—SO2-het, —C(O)H, —Z—NR12—Z—O(C1-C6)alkyl, —Z—NR12—Z—NR12R13, —Z—NR12—(C3-C6)cycloalkyl, —Z—N(Z—O(C1-C6)alkyl)2, —SO2R12, —SOR12, —SR12, —SO2NR12R13, —O—C(O)—(C1-C4)alkyl, —O—SO2—(C1-C4)alkyl, -halo or —CF3;
- Z for each occurrence is independently a) —(C0-C6)alkyl, b) —(C2-C6)alkenyl or c) —(C2-C6)alkynyl;
- R2 is a) —H, b) -halo, c) —OH, d) —(C1-C6)alkyl substituted with 0 or 1 —OH, e) —NR12R13, f) —Z—C(O)O(C1-C6)alkyl, g) —Z—C(O)NR12R13, h) —O—(C1-C6)alkyl, i) —Z—O—C(O)—(C1-C6)alkyl, j) —Z—O—(C1-C3)alkyl-C(O)—NR12R13, k) —Z—O—(C1-C3)alkyl-C(O)—O(C1-C6)alkyl, l) —O—(C2-C6)alkenyl, m) —O—(C2-C6)alkynyl, n) —O—Z-het, o) —COOH, p) —C(OH)R12R13 or q) —Z—CN;
- R3 is a) —H, b) —(C1-C10)alkyl wherein 1 or 2 carbon atoms, other than the connecting carbon atom, may optionally be replaced with 1 or 2 heteroatoms independently selected from S, O and N and wherein each carbon atom is substituted with 0, 1 or 2 Ry, c) —(C2-C10)alkenyl substituted with 0, 1 or 2 Ry, d) —(C2-C10)alkynyl wherein 1 carbon atom, other than the connecting carbon atom, may optionally be replaced with 1 oxygen atom and wherein each carbon atom is substituted with 0, 1 or 2 Ry, e) —CH═C═CH2, f) —CN, g) —(C3-C6)cycloalkyl, h) —Z-aryl, i) —Z-het, j) —C(O)O(C1-C6)alkyl, k) —O(C1-C6)alkyl, l) —Z—S—R12, m) —Z—S(O)—R12, n) —Z—S(O)2—R12, o) —CF3p) —NR12O—(C1-C6)alkyl or q) —CH2ORy;
- provided that one of R2 and R3 is absent when there is a double bond between CR2R3 (the 7 position) and the F moiety (the 8 position) of the C-ring;
- Ry for each occurrence is independently a) —OH, b) -halo, c) —Z—CF3, d) —Z—CF(C1-C3 alkyl)2, e) —CN, f) —NR12R13, g) —(C3-C6)cycloalkyl, h) —(C3-C6)cycloalkenyl, i) —(C0-C3)alkyl-aryl, j) -het or k) —N3;
- or R2 and R3 are taken together to form a) ═CHR11, b) ═NOR11, c) ═O, d) ═N—NR12, e) ═N—NR12—C(O)—R12, f) oxiranyl or g) 1,3-dioxolan-4-yl;
- R4 and R5 for each occurrence are independently a) —H, b) —CN, c) —(C1-C6)alkyl substituted with 0 to 3 halo, d) —(C2-C6)alkenyl substituted with 0 to 3 halo, e) —(C2-C6)alkynyl substituted with 0 to 3 halo, f) —O—(C1-C6)alkyl substituted with 0 to 3 halo, g) —O—(C2-C6)alkenyl substituted with 0 to 3 halo, h) —O—(C2-C6)alkynyl substituted with 0 to 3 halo, i) halo, j) —OH, k) (C3-C6)cycloalkyl or l) (C3 -C6)cycloalkenyl;
- or R4 and R5 are taken together to form ═O;
- R6 is a) —H, b) —CN, c) —(C1-C6)alkyl substituted with 0 to 3 halo, d) —(C2-C6)alkenyl substituted with 0 to 3 halo, e) —(C2-C6)alkynyl substituted with 0 to 3 halo or f) —OH;
- R7 and R16 for each occurrence are independently a) —H, b) -halo, c) —CN, d) —(C1-C6)alkyl substituted with 0 to 3 halo, e) —(C2-C6)alkenyl substituted with 0 to 3 halo or f) —(C2-C6)alkynyl substituted with 0 to 3 halo;
- provided that R7 is other than —CN or -halo when D is NR7;
- or R7 and R16 are taken together to form ═O;
- R8, R9, R14 and R15 for each occurrence are independently a) —H, b) -halo, c) (C1-C6)alkyl substituted with 0 to 3 halo, d) —(C2-C6)alkenyl substituted with 0 to 3 halo, e) —(C2-C6)alkynyl substituted with 0 to 3 halo, f —CN, g) —(C3-C6)cycloalkyl, h) —(C3-C6)cycloalkenyl, i) —OH, j) —O—(C1-C6)alkyl, k) —O—(C1-C6)alkenyl, l) —O—(C1-C6)alkynyl, m) —NR12R13, n) —C(O)OR12 or o) —C(O)NR12R13;
- or R8 and R9 are taken together on the C-ring to form ═O;
- provided that when m is 2, only one set of R8 and R9 are taken together to form ═O;
- or R14 and R15 are taken together to form ═O;
- provided that when R14 and R15 are taken together to form ═O, D is other than CR7 and E is other than C;
- R10 is a) —(C1-C10)alkyl substituted with 0 to 3 substituents independently selected from -halo, —OH and —N3, b) —(C2-C10)alkenyl substituted with 0 to 3 substituents independently selected from -halo, —OH and —N3, c) —(C2-C10)alkynyl substituted with 0 to 3 substituents independently selected from -halo, —OH and —N3, d) -halo, e) —Z—CN, f) —OH, g) —Z-het, h) —Z—NR12R13, i) —Z—C(O)-het, j) —Z—C(O) —(C1-C6)alkyl, k) —Z—C(O)—NR12R13, l) —Z—C(O) —NR12—Z—CN, m) —Z—C(O)—NR12—Z-het, n) —Z—C(O) —NR12—Z-aryl, o) —Z—C(O) —NR12—Z—NR12R13, p) —Z—C(O)—NR12—Z—O(C1-C6)alkyl, q) —(C0-C6)alkyl-C(O)OH, r) —Z—C(O)O(C1-C6)alkyl, s) —Z—O—(C0-C6)alkyl-het, t) —Z—O—(C0-C6)alkyl-aryl, u) —Z—O—(C1-C6)alkyl substituted with 0 to 2 Rx, v) —Z—O—C1-C6)alkyl-CH(O), w) —Z—O—(C1-C6)alkyl-NR12-het, x) —Z—O—Z-het-Z-het, y) —Z—O—Z-het-Z—NR12R13, z) —Z—O—Z-het-C(O)-het, a1) —Z—O—Z—C(O)-het, b1) —Z—O—Z—C(O)-het-het, c1) —Z—O—Z—C(O)—(C1-C6)alkyl, d1) —Z—O—Z—C(S)—NR12R13, e1) —Z—O—Z—C(O)—NR12R13, f1) —Z—O—Z—(C1-C3)alkyl-C(O) —NR12R13, g1) —Z—O—Z—C(O)—O(C1-C6)alkyl, h1) —Z—O—Z—C(O)—OH, i1) —Z—O—Z—C(O)—NR12—O(C1-C6)alkyl, j1) —Z—O—Z—C(O)—NR12—OH, k1) —Z—O—Z—C(O)—NR12—Z—NR12R13, l1) —Z—O—Z—C(O)—NR12—Z-het, m1) —Z—O—Z—C(O)—NR12—SO2—(C1-C6)alkyl, n1) —Z—O—Z—C(═NR12)(NR12R13), o1) —Z—O—Z—C(═NOR12)(NR12R13), p1) —Z—NR12—C(O)—O—Z—NR12R13, q1) —Z—S—C(O)—NR12R13, r1) —Z—O—SO2—(C1-C6)alkyl, S1) —Z—O—SO2-aryl, t1) —Z—O—SO2—NR12R13, u1) —Z—O—SO2—CF3, v1) —Z—NR12C(O)OR13 or w1) —Z—NR12C(O)R13;
- or R9 and R10 are taken together on the moiety of formula A-5 to form a) ═O or b) ═NOR12;
- R11 is a) —H, b) —(C1-C5)alkyl, c) —(C3-C6)cycloalkyl or d) —(C0-C3)alkyl-aryl;
- R12 and R13 for each occurrence are each independently a) —H, b) —(C1-C6)alkyl wherein 1 or 2 carbon atoms, other than the connecting carbon atom, may optionally be replaced with 1 or 2 heteroatoms independently selected from S, O and N and wherein each carbon atom is substituted with 0 to 6 halo, c) —(C2-C6)alkenyl substituted with 0 to 6 halo or d) —(C1-C6)alkynyl wherein 1 carbon atom, other than the connecting carbon atom, may optionally be replaced with 1 oxygen atom and wherein each carbon atom is substituted with 0 to 6 halo;
- or R12 and R13 are taken together with N to form het;
- or R6 and R14 or R15 are taken together to form 1,3-dioxolanyl;
- aryl is a) phenyl substituted with 0 to 3 Rx, b) naphthyl substituted with 0 to 3 Rx or c) biphenyl substituted with 0 to 3 Rx;
- het is a 5-,6- or 7-membered saturated, partially saturated or unsaturated ring containing from one (1) to three (3) heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
- and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocycle;
- and the nitrogen may be in the oxidized state giving the N-oxide form;
- and substituted with 0 to 3 Rx;
- Rx for each occurrence is independently a) -halo, b) —OH, c) —(C1-C6)alkyl, d) —(C2-C6)alkenyl, e) —(C2-C6)alkynyl, f) —O(C1-C6)alkyl, g) —O(C2-C6)alkenyl, h) —O(C2-C6)alkynyl, i) —(C0-C6)alkyl-NR12R13, j) —C(O)—NR12R13, k) —Z—SO2R12, l)—Z—SOR12, m) —Z—SR12, n) —NR12—SO2R13, o) —NR12—C(O)—R13, p) —NR12—OR13, q) —SO2—NR12R13, r) —CN, s) —CF3, t) —C(O)(C1-C6)alkyl, u) ═O, v) —Z—SO2-phenyl or w) —Z—SO2-het′;
- aryl′ is phenyl, naphthyl or biphenyl;
- het′ is a 5-,6- or 7-membered saturated, partially saturated or unsaturated ring containing from one (1) to three (3) heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
- and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocycle;
- provided that:
- 1) X—R1 is other than hydrogen or methyl;
- 2) when R9 and R10 are substituents on the A-ring, they are other than mono- or di-methoxy;
- 3) when R2 and R3 are taken together to form ═CHR11 or ═O wherein R11 is —O(C1-C6)alkyl, then —X—R1 is other than (C1-C4)alkyl;
- 4) when R2 and R3 taken together are C═O and R9 is hydrogen on the A-ring;
- or when R2 is hydroxy, R3 is hydrogen and R9 is hydrogen on the A-ring, then R10 is other than —O—(C1-C6)alkyl or —O—CH2-phenyl at the 2-position of the A-ring;
- 5) when X—R1 is (C1-C4)alkyl, (C2-C4)alkenyl or (C2-C4)alkynyl, R9 and R10 are other than mono-hydroxy or ═O, including the diol form thereof, when taken together;
- and
- 6) when X is absent, R1 is other than a moiety containing a heteroatom independently selected from N, O or S directly attached to the juncture of the B-ring and the C-ring.
A compound of formula VII
- 81
- or an isomer thereof;
- wherein ———— is an optional bond;
- X′ is —CH2—;
- R′1 is phenyl substituted with 0, 1 or 2 R′x;
- R′2 is —OH;
- R′3 is a) —(C1-C6)alkyl substituted with 0 or 1 R′y or b) —(C2-C6)alkynyl substituted with 0 or 1 R′y;
- R′y is —CF3;
- or R′2 and R′3 are taken together to form ═O;
- R′9 is —H;
- R′10 is a) -halo, b) —C(O)OH, c) —C(O)O(C1-C6)alkyl, d) —C(O)—NR′12R′13, e) —CN, f) —OH or g) —O—(C1-C3)alkyl;
- R′x is a) -halo, b) —OH, c) —(C1-C6)alkyl, d) —CN, e) —CF3, f) —(C0-C6)alkyl-NR′2R′13, g) —C(O)—NR′12R′13, h) —NR′12—SO2R′13, i) —NR′12—C(O)—R′13, j) —SO2R′12 or k) —SO2—NR′12R′13;
- R′12 and R′13 for each occurrence are each independently a) —H or b) —(C1-C6)alkyl.
A compound of formula VIII
- 82
- or an isomer thereof;
- wherein D′ is C;
- X′ is —CH2—;
- R′1 is phenyl substituted with 0 to 2 R′x;
- R′5, R′7, R′8, R′9, R′15 and R′16 for each occurrence are independently a) —H, b) —O—(C1-C6)alkyl, c) —(C1-C6)alkyl or d) halo;
- R′10 is a) -halo, b) —CN, c) —OH, d) —C(O)—NR′12R′13, e) —C(O)—NR′12—Z′-het wherein het is substituted with 0 or 1 R′x, f)—C(O)—NR′12—Z′-aryl wherein aryl is substituted with 0 or 1 R′x, g) —O—(C0-C6)alkyl-het wherein het is substituted with 0 or 1 R′x, or h) —O—(C0-C6)alkyl-aryl wherein aryl is substituted with 0 or 1 R′x;
- Z′ is a) —(C0-C6)alkyl, b) —(C2-C6)alkenyl, or c) —(C2-C6)alkynyl;
- R′x is a) -halo, b) —OH, c) —(C1-C6)alkyl, d) —CN, e) —CF3, f) —(C0-C6)alkyl-NR′12R′13, g) —C(O)—NR′12R′13, h) —NR′12—SO2R′13, i) —NR′12—C(O)—R′13, j) —SO2R′12 or k) —SO2—NR′12R′13;
- R′12 and R′13 for each occurrence are each independently a) —H or b) —(C1-C6)alkyl;
- aryl is phenyl;
- het is a 5-,6- or 7-membered saturated, partially saturated or unsaturated ring containing from one (1) to three (3) heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
A method for the treatment of an inflammatory disease in a mammal and for reducing the undesirable side effects of said treatment which comprises:
- administering to said mammal therapeutically effective amounts of a glucocorticoid receptor modulator and a glucocorticoid receptor agonist.
Dependencies are inferred from the claim text.